肥胖患者SCH、血清维生素D水平与NAFLD严重程度关系的研究

doi:10.3877/cma.j.issn.2095-9605.2023.02.004

目的

探讨肥胖患者亚临床甲状腺功能减退（SCH）、血清维生素D水平和非酒精性脂肪肝（NAFLD）严重程度的相关性。

方法

回顾性分析2021年11月1日至2022年3月31日在安徽医科大学第二附属医院减重代谢外科就诊的120例肥胖合并NAFLD患者的临床资料，根据是否存在SCH，将患者分为SCH组和对照组。进一步根据维生素D水平进行亚组分析：SCH-VD不足组、SCH-VD缺乏组、对照-VD不足组、对照-VD缺乏组。NAFLD的诊断采用肝脏超声检查，腹部定量CT用于评估肝脏脂肪含量，并使用肝脂肪指数（FLI）和FIB-4（fibrosis index based on the 4 factor）评分预测NALFD肝脂肪变性和肝纤维化程度。

结果

SCH组患者的FLI、FIB-4和肝脏脂肪含量明显高于对照组（P<0.05），维生素D水平显著低于对照组（P<0.05），亚组分析显示SCH合并维生素D缺乏患者的FLI、FIB-4和肝脏脂肪含量更高（P<0.05）。相关性分析显示血清促甲状腺激素（TSH）与FLI、FIB-4和肝脏脂肪含量呈正相关（P=0.030，r=0.199；P<0.001，r=0.387；P=0.004，r=0.261），而维生素D水平与FLI、FIB-4和肝脏脂肪含量呈负相关（P=0.012，r=-0.229；P=0.249，r=-0.106；P<0.001，r=-0.363），维生素D水平与TSH的相关性分析显示二者呈负相关（P<0.001, r=-0.326）。此外，多元回归分析显示维生素D缺乏是重度NAFLD的独立危险因素（P=0.034，OR=0.615）。

结论

SCH和维生素D缺乏与肥胖患者的NAFLD密切相关，而且维生素D缺乏是重度NAFLD的独立危险因素，因此对于肥胖伴NAFLD患者，建议完善甲状腺功能以及血清维生素D检查，以便即时干预。

关键词: 非酒精性脂肪肝, 亚临床甲状腺功能减退, 维生素D, 肥胖

Objective

To analyze the correlation between subclinical hypothyroidism (SCH), serum vitamin D levels, and the severity of non-alcoholic fatty liver disease (NAFLD) in patients with obesity.

Methods

Clinical data of 120 obese patients with NAFLD who visited the Department of Weight and Metabolism Surgery of the Second Affiliated Hospital of Anhui Medical University from November 1, 2021 to March 31, 2022, were retrospectively analyzed. Patients were divided into SCH group and control group based on the presence of SCH, and further subgroup analysis was performed based on the vitamin D levels: SCH-Vitamin D deficient group, SCH-Vitamin D insufficient group, control-Vitamin D deficient group, and control-Vitamin D insufficient group. Liver ultrasonography was used to diagnose NAFLD, QCT was used to evaluate liver fat content, and the Fatty Liver Index (FLI) and Fibrosis Index Based on the 4 Factor (FIB-4) score were used to predict NAFLD liver fat degeneration and liver fibrosis.

Results

The FLI, FIB-4, and liver fat content were significantly higher in the SCH group compared to the control group (P<0.05), whereas vitamin D levels were lower in the SCH group (P<0.05). Subgroup analysis revealed that patients with both SCH and vitamin D deficiency had higher FLI, FIB-4, and liver fat content (P<0.05). Correlation analysis demonstrated a positive correlation between thyroid stimulating hormone (TSH) and FLI, FIB-4, as well as liver fat content (P=0.030, r=0.199; P<0.001, r=0.387; P=0.004, r=0.261), while vitamin D exhibited a negative correlation with FLI, FIB-4, and liver fat content (P=0.012, r=-0.229; P=0.249, r=-0.106; P<0.001, r=-0.363). Additionally, the correlation analysis between vitamin D levels and TSH demonstrated a negative correlation (P<0.001, r=-0.326). Furthermore, vitamin D (P=0.034, OR=0.615) was identified as an independent risk factor for severe NAFLD.

Conclusions

Our findings suggest a close association between SCH, vitamin D deficiency, and NAFLD in obese patients. Vitamin D deficiency emerges as an independent risk factor for severe NAFLD.Therefore, for obese patients with NAFLD, it is recommended to improve thyroid function and serum vitamin D levels to facilitate timely intervention.

Key words: Nonalcoholic fatty liver disease, Subclinical hypothyroidism, Vitamin D, Morbid obesity

表1 SCH组和对照组临床资料比较

指标	SCH组（n=49）	对照组（n=71）	t/χ²值	P值
年龄（岁）	33.88±8.52	28.94±6.75	-3.531	0.285
性别（男/女）	10/39	15/56	0.009	0.924
体重（kg）	113.08±22.76	111.58±17.67	-0.406	0.311
BMI（kg/m²）	41.58±5.77	39.37±3.70	-2.554	0.008
腰围（cm）	125.77±12.82	120.92±10.18	-2.305	0.184
TG（mmol/L）	2.23±1.73	1.86±1.99	-1.330	0.433
TC（mmol/L）	4.75±0.73	4.83±0.99	0.443	0.186
TSH（mIU/L）	7.08±3.32	2.47±1.04	-10.975	<0.001
维生素D（ng/mL）	11.86±3.91	16.72±5.29	4.713	0.010
ALT（U/L）	41.02±30.44	53.18±57.03	1.364	0.044
AST（U/L）	44.63±22.08	34.24±26.16	-2.076	0.643
GGT（U/L）	81.90±54.33	44.18±23.45	-5.198	<0.001
PLT（10³）	257.90±44.72	299.34±65.55	3.848	0.279
肝脏脂肪含量（%）	24.60±8.63	16.86±5.70	-5.920	<0.001
FLI	55.28±29.14	33.72±20.70	-4.741	<0.001
LIB-4	1.00±0.50	0.48±0.20	-7.861	<0.001

表1 SCH组和对照组临床资料比较

指标	SCH组（n=49）	对照组（n=71）	t/χ²值	P值
年龄（岁）	33.88±8.52	28.94±6.75	-3.531	0.285
性别（男/女）	10/39	15/56	0.009	0.924
体重（kg）	113.08±22.76	111.58±17.67	-0.406	0.311
BMI（kg/m²）	41.58±5.77	39.37±3.70	-2.554	0.008
腰围（cm）	125.77±12.82	120.92±10.18	-2.305	0.184
TG（mmol/L）	2.23±1.73	1.86±1.99	-1.330	0.433
TC（mmol/L）	4.75±0.73	4.83±0.99	0.443	0.186
TSH（mIU/L）	7.08±3.32	2.47±1.04	-10.975	<0.001
维生素D（ng/mL）	11.86±3.91	16.72±5.29	4.713	0.010
ALT（U/L）	41.02±30.44	53.18±57.03	1.364	0.044
AST（U/L）	44.63±22.08	34.24±26.16	-2.076	0.643
GGT（U/L）	81.90±54.33	44.18±23.45	-5.198	<0.001
PLT（10³）	257.90±44.72	299.34±65.55	3.848	0.279
肝脏脂肪含量（%）	24.60±8.63	16.86±5.70	-5.920	<0.001
FLI	55.28±29.14	33.72±20.70	-4.741	<0.001
LIB-4	1.00±0.50	0.48±0.20	-7.861	<0.001

表2 不同维生素D水平下肝脏相关评分和腹部CT评估差异

指标	SCH-VD缺乏组（n=18）	SCH-VD不足组（n=31）	对照-VD缺乏组（n=14）	对照-VD不足组（n=57）
FLI ^c	70.43±30.73	46.49±24.62	40.16±18.72	32.14±21.00
FIB-4^abcde	1.09±0.31	0.95±0.58	0.49±0.17	0.48±0.21
肝脏脂肪含量（%）^ce	28.11±8.82	22.56±7.95	20.94±5.99	15.86±5.21
维生素D^acd	8.78±0.79	14.85±3.33	8.73±0.76	18.67±3.92

表2 不同维生素D水平下肝脏相关评分和腹部CT评估差异

指标	SCH-VD缺乏组（n=18）	SCH-VD不足组（n=31）	对照-VD缺乏组（n=14）	对照-VD不足组（n=57）
FLI ^c	70.43±30.73	46.49±24.62	40.16±18.72	32.14±21.00
FIB-4^abcde	1.09±0.31	0.95±0.58	0.49±0.17	0.48±0.21
肝脏脂肪含量（%）^ce	28.11±8.82	22.56±7.95	20.94±5.99	15.86±5.21
维生素D^acd	8.78±0.79	14.85±3.33	8.73±0.76	18.67±3.92

图1 肝脏评分与TSH、维生素D的相关性

图2 维生素D与TSH的相关性

表3 重度脂肪肝的相关危险因素分析

影响因素	β	Wald值	P值	OR值	95% CI
年龄	0.177	1.016	0.313	1.194	0.846~1.684
BMI	0.774	2.346	0.126	2.168	0.805~5.838
HOMA-IR	-0.450	1.738	0.187	0.638	0.327~1.245
TSH	-0.029	0.007	0.932	0.971	0.500~1.886
维生素D	-0.486	4.505	0.034	0.615	0.393~0.963
ALT	0.014	0.184	0.668	1.014	0.951~1.082
AST	0.029	0.223	0.637	1.029	0.914~1.159
GGT	0.096	2.974	0.085	1.100	0.987~1.226

表3 重度脂肪肝的相关危险因素分析

影响因素	β	Wald值	P值	OR值	95% CI
年龄	0.177	1.016	0.313	1.194	0.846~1.684
BMI	0.774	2.346	0.126	2.168	0.805~5.838
HOMA-IR	-0.450	1.738	0.187	0.638	0.327~1.245
TSH	-0.029	0.007	0.932	0.971	0.500~1.886
维生素D	-0.486	4.505	0.034	0.615	0.393~0.963
ALT	0.014	0.184	0.668	1.014	0.951~1.082
AST	0.029	0.223	0.637	1.029	0.914~1.159
GGT	0.096	2.974	0.085	1.100	0.987~1.226

[1]	Xie F, Pei Y, Zhou Q, et al. Comparison of obesity-related indices for identifying nonalcoholic fatty liver disease: a population-based cross-sectional study in China [J]. Lipids Health Dis, 2021, 20(1): 132.
[2]	Wijarnpreecha K, Panjawatanan P, Aby E, et al. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity [J]. Maturitas, 2019, 124: 48-54.
[3]	Chukur OO, Pasyechko NV, Bob AO, et al. ASSOcapital ES, CyrillicIation between vitamin d status and metabolic disorders in premenopausal women with autoimmune hypothyroid disease [J]. Wiad Lek, 2021, 74(7): 1612-1616.
[4]	Lu S, Guan Q, Liu Y, et al. Role of extrathyroidal TSHR expression in adipocyte differentiation and its association with obesity [J]. Lipids Health Dis, 2012, 11(1): 17.
[5]	Sergeev IN. Vitamin D Status and Vitamin D-Dependent Apoptosis in Obesity [J]. Nutrients, 2020, 12(5).
[6]	Răcătăianu N, Leach NV, Bolboacă SD, et al. Vitamin D deficiency, insulin resistance and thyroid dysfunction in obese patients: is inflammation the common link? [J]. Scand J Clin Lab Invest, 2018, 78(7-8): 560-565.
[7]	Holick MF. Vitamin D deficiency [J]. N Engl J Med, 2007, 357(3): 266-281.
[8]	Pezeshki B, Ahmadi A, Karimi A. The Effect of Vitamin D Replacement on Patient with Subclinical Hypothyroidism: A Pilot Randomized Clinical Trial [J]. Galen Med J, 2020, 9: e1592.
[9]	Yan F, Wang Q, Lu M, et al. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity [J]. J Hepatol, 2014, 61(6): 1358-64.
[10]	Mantovani A, Nascimbeni F, Lonardo A, et al. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis [J]. Thyroid, 2018, 28(10): 1270-1284.
[11]	Song RH, Wang B, Yao QM, et al. The Impact of Obesity on Thyroid Autoimmunity and Dysfunction: A Systematic Review and Meta-Analysis [J]. Front Immunol, 2019, 10: 2349.
[12]	Zhang H, Shen Z, Lin Y, et al. Vitamin D receptor targets hepatocyte nuclear factor 4alpha and mediates protective effects of vitamin D in nonalcoholic fatty liver disease [J]. J Biol Chem, 2020, 295(12): 3891-3905.
[13]	Tian L, Song Y, Xing M, et al. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway [J]. Hepatology, 2010, 52(4): 1401-9.
[14]	Lee Y, Park Y J, Ahn HY, et al. Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile [J]. Endocr J, 2013, 60(8): 977-83.
[15]	Yodoshi T, Orkin S, Arce-Clachar AC, et al. Vitamin D deficiency: prevalence and association with liver disease severity in pediatric nonalcoholic fatty liver disease [J]. Eur J Clin Nutr, 2020, 74(3): 427-435.
[16]	Yuan S, Larsson SC. Inverse Association Between Serum 25-Hydroxyvitamin D and Nonalcoholic Fatty Liver Disease [J]. Clin Gastroenterol Hepatol, 2023, 21(2):398-405.e4.

[1]	陈嘉婷, 杜美君, 石冰, 黄汉尧. 母体系统性疾病对新生儿唇腭裂发生的影响[J]. 中华口腔医学研究杂志(电子版), 2024, 18(04): 262-268.
[2]	孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[3]	李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[4]	杨波, 胡旭, 何金艳, 谢铭. 腹腔镜袖状胃切除术管胃固定研究现状[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 452-455.
[5]	吉顺富, 汤晓燕, 徐进. 腹腔镜近端胃癌根治术中拓展胃后间隙在肥胖患者中的应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 393-396.
[6]	张秋子, 胡利梅, 陈雅茹, 左丽, 任卫东. 维生素D水平与亚急性甲状腺炎预后的相关性研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 217-219.
[7]	颜帅, 胡旭, 苟晓梅, 谢铭. 腹腔镜胃袖状切除术后并发症处置策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 220-224.
[8]	白若靖, 郭军. 维生素D对肺部疾病临床意义的研究进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 659-662.
[9]	房桂彬, 肖进, 傅光涛, 郑秋坚. 老年髋部骨折患者术后1年行走能力的影响因素分析[J]. 中华老年骨科与康复电子杂志, 2024, 10(05): 273-280.
[10]	唐小久, 胡曼, 许必君, 肖亚. 肥胖合并胃食管反流病患者严重程度与其焦虑抑郁及营养状态的相关性研究[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 360-364.
[11]	王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
[12]	李娟, 廖江涛, 吴聃. 老年人结直肠腺瘤与血脂及非酒精性脂肪肝的相关性研究[J]. 中华胃肠内镜电子杂志, 2024, 11(03): 186-190.
[13]	颜宥彤, 赵锐, 万谦益, 张贵祥, 沈弘毅, 程中, 陈亿. GLP-1受体激动剂——司美格鲁肽的应用及安全性[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 88-93.
[14]	杨宁琍, 梁辉. 中国肥胖代谢外科个案管理教育培训现状及展望[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 94-99.
[15]	周彪, 李政奇, 孟化. 肥胖与内镜下减重治疗研究进展[J]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 100-107.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Study on the relationship between SCH, serum vitamin D levels and the severity of NAFLD in patients with obesity

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Study on the relationship between SCH, serum vitamin D levels and the severity of NAFLD in patients with obesity